The cytokine interleukin-1 (IL-1) is primarily to blame for a severe type of juvenile arthritis, according to Pascual and colleagues on page 1479. Blocking IL-1 activity in children with systemic onset juvenile idiopathic arthritis (SoJIA) completely resolved disease symptoms in a majority of children who had failed to respond to conventional treatments.

SoJIA is a systemic inflammatory disease of unknown etiology that can cause long-term arthritis in children. The pathogenesis of the disease is unclear, although increases in the inflammatory cytokine IL-6 have been reported in the blood of these patients. Currently the most effective therapy for SoJIA is long-term treatment with steroids, which carries with it the risk of growth retardation, osteoporosis, and obesity.

Pascual and colleagues now reveal a central role for IL-1---a cytokine that plays a major role in many inflammatory and autoimmune diseases---in the pathology of SoJIA. They show that serum from SoJIA patients provokes healthy cells to increase expression of IL-1, but no other cytokines. In addition, stimulated peripheral blood cells from children with SoJIA produced more IL-1, but not IL-6 or TNF, compared with cells from healthy children.

These results prompted Pascual and colleagues to treat these patients with an IL-1 receptor antagonist (Anakinra). The results were remarkable---symptoms were completely resolved or significantly improved in all children with active arthritis, with only one later case of reversion.

The mechanism behind the increased IL-1 production in SoJIA is unknown. As SoJIA is not an inherited disease, the defect is likely to be different from familial IL-1--triggered inflammatory diseases in which a mutated NALP3 can no longer control the activation of caspase-1, which cleaves the IL-1β precursor into the active cytokine. The authors are now looking for the serum component that turns on IL-1.
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